TABLE 1.

Main clinical trials of Chloroquine for Covid-19.

	Author	Design	Country	End point	References
1	Philippe Gautret et al.	Open-label non-randomized clinical trial	France	Viral load	Gautret et al. (2021)
2	RECOVERY Collaborative Group et al.	Randomized, controlled, open-label platform trial	United Kingdom	Mortality	Group et al. (2020)
3	Duvignaud A. et al.	Phase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label controlled superiority trial	France	Prevent hospitalisation or death	Duvignaud et al. (2020)
4	Prasan Kumar Panda et al.	Open label, Parallel arm design, stratified randomised controlled trial	India	Severe category	Panda et al. (2020)
5	Xi Liu et al.	Prospective, open-label, randomized controlled, multicenter clinical study	China	Clinical recovery time	Liu et al. (2020)
6	Mayla Gabriela Silva Borba et al.	Parallel, double-masked, randomized, phase IIb clinical trial	Brazil	Safety and lethality outcomes	Borba et al. (2020)
7	Bharath Kumar Tirupakuzhi Vijayaraghavan et al.	Multi-centre open-label parallel group randomized controlled trial	India et al.	The proportion of healthcare workers developing laboratory confirmed COVID-19 infection within 6 months of randomization	Tirupakuzhi Vijayaraghavan et al. (2020)
8	Alok Thakar et al.	Randomized clinical trial	India	Clinical progression and outcomes	Thakar et al. (2021)
9	Sherief Abd-Elsalam et al.	Randomized clinical trial	Egypt	Recovery within 28 days, the need for mechanical ventilation, and death	Abd-Elsalam et al. (2021)
10	Álvaro Réa-Neto et al.	Randomized, open-label, controlled, phase III trial	Brazil	Clinical status measured on day 14	Rea-Neto et al. (2021)
11	Weehuizen JM et al.	Controlled, open label, cluster-randomized, superiority trial	Netherlands	Disease progression	Weehuizen and Hoepelman (2020)